The 3rd Asian Pneumococcal Symposium

Program (tentative)

Day 1: Thursday, December 02, 2021

Welcome Remarks09:00-09:05

Kazunori Oishi
President of the 3rd Asian Pneumococcal Symposium, Toyama Institute of Health

Session 1:
Capsular Nomenclature

SE1-1Capsule Expression among Oral Streptococci
Kazunori Oishi
President of the 3rd Asian Pneumococcal Symposium, Toyama Institute of Health
SE1-2Two independent cases of invasive disease in adults caused by Streptococcus oralis expressing serotype 3 pneumococcal capsule
Kei Kasahara
Nara Medical University, Japan

Session 2:
Genetics and Genomics

SE2-1Predication of β-lactam resistance phenotype
Jie Feng
Institute of Microbiology, Chinese Academy of Sciences, China
SE2-2 Pneumococcal virulence factors by molecular evolutionary analysis
Masaya Yamaguchi
Osaka University Graduate School of Dentistry, Japan

Session 3:
Pneumococcus-host Interactions

SE3-1Survival strategy of S. pneumoniae by hijacking host autophagy
Michinaga Ogawa
National Institute of Infectious Diseases, Japan
SE3-2Capsule serotype-dependent evasion of resident macrophage capture
Jing-Ren Zhang
Tsinghua University, China

Luncheon Seminar 112:00-13:00

LS-1To be determined
To be determined

Session 4:
Cost Effectiveness of Vaccine

SE4-1Economic evaluation of vaccines and vaccination programs:
guides from global and Japanese experiences
Manabu Akazawa
Meiji Pharmaceutical University, Japan
SE4-2The Health Technology Assessment of pneumococcal vaccination in Japan:
cost-effectiveness and value assessment
Ataru Igarashi
Yokohama City University School of Medicine, Japan

Poster Session 14:00-16:00

APS Plenary Lecture116:00-17:00

PL1-1Nasal delivery of a universal protein antigen identified by CRISPRi-seq induces broad protection from pneumococcal superinfection
Jan-Willem Veening
University of Lausanne, Switzerland

Sponsored Symposium17:00-18:30

SSY-1-1 To be determined
SSY-1-2 To be determined
SSY-1-3 To be determined

Day 2: Friday, December 03, 2021

APS Plenary Lecture 209:00-10:00

PL2-1Pneumococcal-Host Interactions Affecting Carriage and Transmission
Jeff N. Weiser
New York University, USA

Session 5:
Epidemiology 1

SE5-1Global impact of PCV10/13 on invasive pneumococcal disease serotype distribution and incidence rates among children and adults: results from the PSERENADE project
Julia C. Bennet and Maria Garcia Quesada
Johns Hopkins Bloomberg School of Public Health, USA)
SE5-2IPD Surveillance in Adults, Japan
Kazunori Oishi
Toyama Institute of Health

Session 6:
Epidemiology 2

SE6-1Molecular epidemiology of pneumococcal isolates in Japan
Satoshi Nakano
National Institute of Infectious Diseases, Japan
SE6-2Changes in molecular epidemiology in Korea after the introduction of Extended valency PCVs in Korean children
Hyunju Lee
Seoul National University Bundang Hospital, South Korea

Luncheon Seminar 212:00-13:00

Co-sponsored by SHIONOGI & CO.,LTD

Hiroshi YotsuyanagiTokyo University
LS-2To be determined
Kazuhiro Tateda
Toho University of Medicine, Japan

Session 7:
Nasopharyngeal Carriage

SE7-1The low carriage prevalence of pneumococcus among community-dwelling older people
Konosuke Morimoto
Nagasaki University, Japan
SE7-2Using community vaccine type pneumococcal carriage to evaluate the impact of reduced dosing PCV schedules in Vietnam
Lay Myint Yoshida
Nagasaki University, Japan

Session 8:
Sequential Administration of PCV13-PPSV23

SE8-1mmunogenicity study of PCV13-PPSV23 in 65 years of age or older
Momoyo Azuma
Tokushima University Hospital, Japan
SE8-2Pneumococcal vaccination in adult allogeneic hematopoietic stem cell transplant recipients
Keiji Okinaka
National Cancer Center Hospital, Japan

Session 9:
Novel Vaccines

SE9-1ynthesis and delivery of Streptococcus pneumoniae capsular polysaccharides by attenuated Salmonella
Qingke Kong
South Western University, China
SE9-2Broad-spectrum vaccine candidate using bivalent recombinant fusion proteins of Pneumococcal Surface Protein A (PspA) against Streptococcus pneumoniae
Hiroki Nakayama
The Research Foundation for Microbial Diseases of Osaka University, Japan
SE9-3Phase 3 trial to evaluate safety, tolerability and immunogenicity of V114 followed by 23-valent pneumococcal polysaccharide vaccine 6 months later in at-risk adults aged 18–49 years (PNEU-DAY)
L Musey
MSD Co.Ltd., USA
SE9-4Pivotal Study of the Safety, Tolerability, and Immunogenicity of PCV20 in Adults
W Watson
Pfizer Co. Ltd. USA

Joint Session:
Future outlooks of prevention of respiratory infectious diseases:new modalities and scheme

Co-Sponsored by the 25th JSV & Sanofi

Ken J. IshiiDivision of Vaccine Science, Department of Microbiology, and Immunology, The Institute of Medical Science, The University of Tokyo
Kazunori OishiToyama Institute of Health
JSE-1Future Perspectives of Research and Development in Infectious Disease Prevention and Future Expectations of Clinical Applications (tentative)
Norio Ohmagari
National Center for Global Health and Medicine, Japan
JSE-2Past, now and future of monoclonal antibodies: from treatment to prevention in infectious disease (tentative)
Susanna Esposito
Pediatrics at the Faculty of Medicine and Surgery of the University of Parma, Italy
President Office, Toyama Institute of Health
17-1, Nakataikoyama, Imizu City, Toyama
TEL: +81-766-56-5506
FAX: +81-766-56-7326